Overview

• Biopharmaceutical firm's Q4 net product sales rose 72% yr/yr, driven by FILSPARI growth

• Company reported Q4 net income of $2.7 mln, compared to a loss last year

• R&D expenses for Q4 decreased due to lower costs in pegtibatinase and FILSPARI development

Outlook

• Travere expects FDA decision on FILSPARI for FSGS by April 13, 2026

• Company anticipates $25 mln milestone payment from Mirum Pharmaceuticals in H1 2026

Result Drivers

• FILSPARI SALES GROWTH - U.S. net product sales of FILSPARI increased by 108% in Q4, driven by demand from new and repeat prescribers

• R&D EXPENSES - Decrease in R&D expenses attributed to lower costs in pegtibatinase and FILSPARI development as trials advance

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Travere Therapeutics Inc is $42.00, about 50.7% above its February 18 closing price of $27.87

• The stock recently traded at 40 times the next 12-month earnings vs. a P/E of 128 three months ago

Press Release: ID:nBw4MXL2Ca

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)